



Targeting Multicopy Prophage Genes for the Increased Detection of *Borrelia burgdorferi* Sensu Lato (s.l.), the Causative Agents of Lyme Disease, in Blood

Jinyu Shan^{1*†}, Ying Jia^{1†}, Louis Teulières², Faizal Patel¹ and Martha R. J. Clokie^{1*}

OPEN ACCESS

¹ Department of Genetics and Genome Biology, University of Leicester, Leicester, United Kingdom, ² PhelixRD Charity 230 Rue du Faubourg St Honoré, Paris, France

Edited by:

Jie Feng,
Lanzhou University Medical College,
China

Reviewed by:

Yang Wu,
Fudan University, China
Maria Gomes-Solecki,
University of Tennessee Health
Science Center (UTHSC),
United States

Monica E. Embers,
Tulane University, United States

*Correspondence:

Jinyu Shan
js401@le.ac.uk
Martha R. J. Clokie
mrjc1@le.ac.uk

† These authors have contributed
equally to this work

Specialty section:

This article was submitted to
Infectious Diseases,
a section of the journal
Frontiers in Microbiology

Received: 08 January 2021

Accepted: 16 February 2021

Published: 15 March 2021

Citation:

Shan J, Jia Y, Teulières L, Patel F
and Clokie MRJ (2021) Targeting
Multicopy Prophage Genes
for the Increased Detection of *Borrelia
burgdorferi* Sensu Lato (s.l.),
the Causative Agents of Lyme
Disease, in Blood.
Front. Microbiol. 12:651217.
doi: 10.3389/fmicb.2021.651217

The successful treatment of Lyme disease (LD) is contingent on accurate diagnosis. However, current laboratory detection assays lack sensitivity in the early stages of the disease. Because delayed diagnosis of LD incurs high healthcare costs and great suffering, new highly sensitive tests are in need. To overcome these challenges, we developed an internally controlled quantitative PCR (Ter-qPCR) that targets the multicopy terminase large subunit (*terL*) gene encoded by prophages that are only found in LD-causing bacteria. The *terL* protein helps phages pack their DNA. Strikingly, the detection limit of the Ter-qPCR was analytically estimated to be 22 copies and one bacterial cell in bacteria spiked blood. Furthermore, significant quantitative differences was observed in terms of the amount of *terL* detected in healthy individuals and patients with either early or late disease. Together, the data suggests that the prophage-targeting PCR has significant power to improve success detection for LD. After rigorous clinical validation, this new test could deliver a step-change in the detection of LD. Prophage encoded markers are prevalent in many other pathogenic bacteria rendering this approach highly applicable to bacterial identification in general.

Keywords: prophages, Lyme disease, diagnosis, multicopy, *Borrelia*, qPCR

INTRODUCTION

Lyme disease (LD) is the most common tick-born disease with approximately 476,000 patients in the United States annually during 2010–2018 (Kugeler et al., 2021). LD is caused by a group of bacteria classified together as the *Borrelia burgdorferi* sensu lato (s.l.) complex, that comprises a clade of more than 20 species including *B. burgdorferi* sensu stricto (s.s.) which dominates in United States, and *B. garinii* and *B. afzelii* which are prevalent in Europe and Asia. The LD-causing bacteria are generally transmitted to humans after they are bitten by ticks of the *Ixodes* family infected with LD causing *Borrelia*. However, recent reports have raised concerns over *Borrelia* transmission through blood transfusion based on observations that *Borrelia* can survive and circulate in the human bloodstream (Pavia and Plummer, 2018).

Currently, LD diagnosis is based on the overt clinical manifestation of disease in the form of erythema migrans (EM) skin lesions, commonly known as a ‘bull’s-eye’ rash and a history of tick

exposure. Although EM lesions occur in 70 to 80% of infected individuals, only a third of these patients develop the classic ‘bull’s-eye’ rash, and many other types of skin lesions can occur which are easily confused with EM (Chaaya et al., 2016). In addition to the EM uncertainty, other common symptoms of LD such as fatigue, muscle pain, headache, and perceived cognitive dysfunction largely overlap with an array of other diseases, including other tick-borne diseases. One such example is Relapsing Fever (RF), which is caused by close relatives of the LD-causing bacteria, such as *Borrelia miyamotoi* (Wormser et al., 2019). The two *Borrelia* ‘groups’ responsible for LD and RF have caused great concern and clinical confusion, as they are morphologically similar and present with almost indistinguishable clinical symptoms (Bergström and Normark, 2018). Despite this, they respond to different antibiotics and treatment regimens (Koetsveld et al., 2017). Another example of confusion surrounding LD is the co-infection caused by *Bartonella* spp. This genus of bacteria is emerging as an increasingly common human infection (Anderson and Neuman, 1997). Much of the controversy surrounding LD and co-infections with *Bartonella* and/or *B. miyamotoi* is due to the lack of a reliable and sensitive diagnostic method to detect and distinguish between the three groups of bacteria, the LD and RF causing *Borrelia* and *Bartonella* (Schutzer et al., 2019). Therefore, laboratory tests to determine and distinguish between LD and co-infections play a vital role in the correct diagnosis and consequent treatment with different antibiotics.

Scientists have faced several challenges with LD detection including patients presenting with a delayed antibody response and a low number of *Borrelia* cells typically found in human clinical samples (Moore et al., 2016). Although it is particularly difficult to diagnose LD early, it is critical, as it is far easier to treat the disease when it is detected at an early stage (Theel et al., 2019). Bacteria-targeting approaches, such as polymerase chain reaction (PCR) detecting the *Borrelia* chromosomal DNA, can potentially identify early LD but is relatively insensitive detecting only between 30-50% of positive cases, and is therefore deemed to have little clinical utility (Schutzer et al., 2019). The reasons behind the poor sensitivity of the current PCR methods in Lyme detection are twofold; first, the current PCRs target *Borrelia* genomic DNA regions that have only one copy in each bacterium, such as the bacterial 16S rRNA gene, *RecA* gene, and the 5S-23S intergenic regions (Brettschneider et al., 1998; Liveris et al., 2012; Waddell et al., 2016; Lohr et al., 2018; Schutzer et al., 2019). Second, at least some *Borrelia* species are ‘tissue-bound’ and are only transiently found circulating in the blood (Liang et al., 2020).

In response to these diagnostic challenges, we adopted a novel approach, taking advantage of the fact that most pathogenic bacteria carry multiple complete or partial prophages (phages associated with bacteria) (Argov et al., 2019). These prophage sequences can form the bases of a template from which quantitative PCR (qPCR) primers and probes can be designed. It is known that *Borrelia* carry a large number of linear and circular plasmids (comprising between 33-40% of the *Borrelia* genome), among which the cp26 and cp32, and the lp54 linear plasmid, are evolutionarily stable (Casjens et al., 2017). Of these paralogous plasmids, cp32 has been experimentally

determined to be a *Borrelia burgdorferi* prophage thus it is highly likely that many of its homologs are also prophages (Eggers and Samuels, 2000).

In this paper we have demonstrated for the first time in *Borrelia*-related diagnostics that it is possible to overcome the sensitivity challenges associated with LD detection. We highlight the potential of our test to discriminate between healthy volunteers, early LD, and late LD patients. We present data from a systematic and comprehensive study that evaluate the use of the multicopy phage terminase large subunit (*terL*) gene as a molecular marker for the detection of *Borrelia* species. The analytical performance of the *terL*-targeting qPCR (referred to as Ter-qPCR) was thoroughly evaluated, and the test was shown to be able to detect one single *Borrelia* cell from blood samples. The diagnostic potential was evaluated using a set of blood and serum samples collected from healthy volunteers and individuals who were clinically diagnosed with LD.

In summary, we demonstrate that a quantitative phage-based PCR has the potential to change the diagnosis of LD from blood samples. This approach of detecting bacteria-specific phages may be applicable to infections other than LD such as sepsis caused by *Staphylococcus aureus*, *Escherichia coli*, and *Pseudomonas aeruginosa* etc. (Minasyan, 2019), as long as suitable phages are identifiable.

RESULTS AND DISCUSSION

Each *Borrelia* species has a distinct amount of species specific variation in its prophage sequences; thus these prophages can be used as a proxy to identify the bacteria because of the tight correlation between them and the exact prophages found in each *Borrelia* host. As there are multiple prophages per *Borrelia* cell, the detectable signal is higher for prophages than bacteria. Furthermore, evidence suggests that *Borrelia* prophages can be released outside the *Borrelia* cells following encounters with stressors such as antibiotics (Eggers and Samuels, 2000). In this study, we confirmed that *Borrelia* prophages can escape from the bacterial host cell in a spontaneous manner. Taking advantage of the multicopy and free movement of *Borrelia* prophages, the approach to target prophages instead of bacteria will bypass the cryptic and tissue-bound feature that typifies human *Borrelia* infections (Liang et al., 2020). Thus, we have a greater chance of detecting the prophages in blood even when the bacteria may not be present or present in extremely low numbers. In this sense, prophages are somewhat analogous to *Borrelia* ‘footprints’.

Multicopy, *terL* Genes Are Widespread Within *Borrelia* Species

To determine which prophage gene to use as a marker, the *B. burgdorferi* B31 genome was examined and shown to carry the multicopy *terL* gene (NC_000948.1). This gene encodes the *terL* protein which is responsible for packing phage genomes and is essential for phage survival (Sun et al., 2012). The gene was found to be present on seven of the circular plasmids from the cp32 series and on three linear plasmids within B31 genome

TABLE 1 | The prevalence of the *terL* homologs among plasmids residing *Borrelia* species causing Lyme disease (smiley face and ' x ' to denote presence and absence of the *terL* homologs, respectively).

Plasmid	<i>B. burgdorferi</i>	<i>B. afzelii</i>	<i>B. garinii</i>	<i>B. bissettii</i>	<i>B. mayonii</i>	<i>B. bavariensis</i>	<i>B. valaisiana</i>	<i>B. finlandensis</i>	<i>B. spielmanii</i>
cp32-1	☺	☺	x	x	☺	☺	x	x	x
cp32-2	☺	x	x	x	x	x	x	x	x
cp32-3	☺	☺	☺	☺	☺	☺	x	☺	x
cp32-4	☺	☺	x	☺	☺	x	x	☺	x
cp32-5	☺	☺	☺	☺	x	☺	☺	x	x
cp32-6	☺	x	☺	☺	x	x	x	x	x
cp32-7	☺	☺	x	☺	x	☺	x	☺	x
cp32-8	☺	x	x	x	x	x	x	x	x
cp32-9	☺	☺	x	x	x	x	x	x	x
cp32-10	☺	x	☺	x	x	x	☺	x	x
cp32-11	☺	☺	x	☺	x	x	x	x	x
cp32-12	☺	☺	x	x	x	x	x	☺	x
cp32-13	☺	x	x	x	☺	x	x	x	x
cp32-2-7 ^a	x	x	x	x	x	x	☺	x	x
cp32-5 + 1 ^b	☺	x	x	x	x	x	x	x	x
cp32-5-1 ^c	☺	x	x	x	x	x	x	x	x
cp32-3 + 10 ^d	☺	x	x	x	x	x	x	x	x
cp30	x	☺	x	x	x	x	x	x	x
lp17	☺	x	x	x	x	x	x	x	x
cp18	☺	x	x	x	x	x	x	x	x
lp25	x	x	x	x	x	☺	x	x	x
lp28-4	x	x	x	x	x	☺	x	x	x
lp54	☺	x	x	x	x	x	☺	☺	☺
lp56	☺	x	x	x	x	x	x	x	x
Total hits	147	25	14	8	8	6	5	5	1

^acp32-2-7 refers to cp32-2 and cp32-7 as both plasmids have the same compatibility (Casjens et al., 2017). ^bcp32-1 + 5 refers to a fusion plasmid discovered from *B. burgdorferi* JD1 that is made up of two different full-length cp32-1 and cp32-5 fused together to form a circular plasmid (Casjens et al., 2012). ^ccp32-1-5 is another version of cp32-1-5 referring to the fusion of cp32-1 and cp32-5 into a single circular replicon (Brisson et al., 2013). ^dcp32-3 + 10 refers to a fusion plasmid discovered from *B. burgdorferi* B31 that is made up of two different full-length cp32-3 and cp32-10 fused together to form a circular plasmid (Schutzer et al., 2011; Casjens et al., 2012).

(Supplementary Information 1). Blastn analysis revealed that the *terL* homologs are widespread in LD and RF *Borrelia* spp., including *B. miyamotoi*. As summarized in Table 1, the *terL* homologs present in LD *Borrelia* species are mainly located on the cp32 plasmids with E values of zero and query cover of 100%; thus, primer design specific to species was carried out. There are 13 versions of *terL*-bearing cp32 plasmids (cp32-1 to cp32-13), all of which are present in the *B. burgdorferi* spp. In contrast, *B. afzelii* and *B. garinii* encode eight and four such cp32 plasmids, respectively.


TerL homologs are also found in RF and *B. miyamotoi* species (E values ranging from 5e-164 to 0.03 and a query cover ranging from 90% to 5%). Thus, the phage *terL* gene appears to be a useful marker; indeed, it has previously been used as a marker to reveal the evolutionary relationships within prophages of the environmental *Paraburkholderia* (Pratama et al., 2018) species and lytic phages of *Edwardsiella ictaluri*, the causative agent of enteric septicaemia of catfish (Carrias et al., 2011). In summary, the prevalence, amount of variability in the sequence, and multicopy nature of *terL* suggests that it could be a suitable marker to indicate *Borrelia* presence. Therefore, we predicted that a qPCR targeting *terL* homologs will detect *Borrelia* species to the

strain level and distinguish LD *Borrelia* species from RF species and *B. miyamotoi*.

Phylogenetic Analysis of the *terL* Gene

To determine the potential of the *terL* gene as a marker for specific *Borrelia* species, phylogenetic analyses were carried out using neighbor-joining (NJ) (Figure 1) and likelihood (ML) methods (Supplementary Information 2). Both trees were concordant with each other and demonstrated three well-defined clades of LD, RF and *B. miyamotoi*, indicating that the *terL* gene is evolutionary stable and offers resolution at the *Borrelia* species level. As shown in Figure 1, the *terL* gene resolves *Borrelia* into genospecies, revealing an independent sub-group of LD *Borrelia* species that is well-separated from the other RF *Borrelia* group (including *B. miyamotoi*) with statistically a significant bootstrap value.

Encouragingly, and of significant importance to diagnosis and treatment, our analyses show a well-supported resolution within the LD and RF lineages. Moreover, it is important to note that the *terL* phylogenetic tree largely agrees with the 16S rRNA gene based *Borrelia* phylogeny. The only exception being that the 16S tree placed *B. miyamotoi* within the RF clade, while the *terL* tree



places it outside both the LD and RF clades (Takano et al., 2010). This variable phylogenetic position of *B. miyamotoi* indicates that it is distantly related to both LD and RF, but is more closely related to RF than to LD *Borrelia*. This detailed resolution offered by the *terL* gene is useful on two fronts: (1) it reflects the fact that the pathogenesis of *B. miyamotoi* is distinct to RF (Telford et al., 2015); and (2) as *B. miyamotoi* is the only RF *Borrelia* that can be co-transmitted with LD *Borrelia* species by hard-bodied ticks (Ravagnan et al., 2018), it is really useful to have a molecular marker that can distinguish between LD and RF-causing *Borrelia* spp., and *B. miyamotoi*.

To summarize this section, the *terL* based phylogenetic analysis tightly correlates the *Borrelia* species. The phylogenetic power of the *terL* gene combined with the multi-copy nature suggests that it can be developed as a diagnostic marker for accurate identification of LD, and can be used to differentiate LD from related infections and co-infections such as RF and diseases caused by *B. miyamotoi*.

Ter-qPCR Analytical Specificity, Sensitivity, and Efficiency

To maximize the specificity and sensitivity of our test, we designed a set of primers and a probe to the most conserved

regions of *terL* (to target nine out of 13 *terL* copies) (Figure 2 and Supplementary Information 3) (Kralik and Ricchi, 2017). The specificity of the primer/probe was confirmed by Blastn and *in silico* PCR¹. Positive Ter-qPCR results were also obtained from all the LD *Borrelia* strains listed in Table 2. No positive Ter-qPCR was observed from *B. spielmanii*, or RF-causing *Borrelia* strains as listed in Table 2, or other non-*Borrelia* bacterial strains tested, along with and human DNA samples (detail in Supplementary Information 4).

For clinical diagnosis and treatment, it is essential to understand the *Borrelia* load present in the patient, which requires absolute quantification. To develop an absolute quantification assay, we cloned the relevant *terL* fraction into a plasmid (Ter-plasmid) and carried out the Ter-qPCR assay with samples containing background human DNA, this in order to mimic the real clinical samples. We observed a strong linear relationship between the concentration of the Ter-plasmid and Cq ($R^2 = 0.99$) with an amplification efficiency of 99.58% (Figure 3A). B31 DNA dilutions also displayed a robust linear association with Cq values ($R^2 = 0.999$) with an amplification efficiency of 98.64% (Figure 3B). This demonstrates the high efficiency of the Ter-qPCR. A close to 100% amplification

¹<http://insilico.ehu.es/PCR/>




FIGURE 2 | Alignment of the *terL* gene sequence located on the 13 cp32 plasmids (cp32-1 to cp32-13). Identical nucleotides are indicated with an asterisk. Conserved regions of the forward and reverse primers, and probe are highlighted in yellow, green and purple, respectively. Identical primer/probe sequences are present in nine of the *terL* genes, except for those of the cp32-2, cp32-3, cp32-6, and cp32-13 plasmids.

TABLE 2 | *Borrelia* strains used in this study.

Lab number	Isolate name	Scientific name	Source	Disease
B31	B31	<i>Borrelia burgdorferi</i>	Sven Bergström	LD
1	1120	<i>Borrelia duttonii</i>	Sven Bergström	RF
2	Her HS1	<i>Borrelia hensii</i>	Sven Bergström	RF
3	VS185 P9	<i>Borrelia burgdorferi</i>	Sven Bergström	LD
4	NE218	<i>Borrelia valasiana</i>	Sven Bergström	LD
5	ACA1	<i>Borrelia afzelii</i>	Sven Bergström	LD
6	United Kingdom filtered	<i>Borrelia burgdorferi</i>	Sven Bergström	LD
7	190 P9	<i>Borrelia garinii</i>	Sven Bergström	LD
8	China23	<i>Borrelia burgdorferi</i>	Sven Bergström	LD
9	CA128	<i>Borrelia bisettii</i>	Sven Bergström	LD
10	FR64b	<i>Borrelia miyamotoi</i>	CDC, United States	RF
11	HT31	<i>Borrelia miyamotoi</i>	CDC, United States	RF
12	CIP 109134	<i>Borrelia burgdorferi</i>	Institut Pasteur	LD
13	CIP 108855T	<i>Borrelia spielmanii</i>	Institut Pasteur	LD
14	CIP 105366T	<i>Borrelia lusitaniae</i>	Institut Pasteur	LD
15	DSM 21467	<i>Borrelia valasiana</i>	DSMZ	LD
16	DSM 10508	<i>Borrelia afzelii</i>	DSMZ	LD
17	DSM 10534	<i>Borrelia garinii</i>	DSMZ	LD
18	DSM 23469	<i>Borrelia bavariensis</i>	DSMZ	LD
19	Pbi	<i>Borrelia bavariensis</i>	Cecilia Hizo-Teufel	LD
20	NT54	<i>Borrelia bavariensis</i>	Cecilia Hizo-Teufel	LD

LD, Lyme disease; RF, Relapsing fever.

efficiency from both serial dilution experiments confirmed that our standard curve assay was robust and repeatable (Bustin et al., 2009).

In this study, we defined the analytical limit of detection (LoD) as the lowest concentration where at least 95% of the technical replicates were positive in the Ter-qPCR (Wei et al., 2016). The LoD was calculated from serial dilutions of Ter-plasmids. The proportion of Ter-qPCR positive among replicates was directly correlated with the number of plasmid copies per reaction (**Supplementary Figure 5**). For example, one copy of the Ter-plasmid led to two positives out of 10 replicates, while 20 and 40 copies generated 9 and 10 positives out of 10 replicates, respectively. Probit analysis via the SPSS package was used to estimate the LoD and was found to be 22 copies per PCR (Pavšič et al., 2016).

DNA Extraction Methods Matter: *in vitro* Spiked Blood Samples

Another challenge in detecting bacteria from blood samples is the successful extraction of DNA that forms the PCR target. It is well-known that DNA extraction from blood samples plays a pivotal role in the success of PCR diagnosis of bacterial infections (Opota et al., 2015). It is also true that PCR assays may fail to amplify if bacteria are sparse, or if an inappropriate DNA extraction method was adopted that favored an overwhelming dominance of human DNA in the final DNA product (Gosiewski et al., 2014). To find the most suitable DNA extraction method, three blood DNA extraction methods were applied to blood samples spiked



with serial dilutions of *Borrelia* cells and assessed by qPCR. We determined the best DNA extraction method by assessing each sample in order to determine the highest detectable phage copy number from the *Borrelia* spiked blood.

To gain an insight into the potential performance of the Ter-qPCR with patients, the Ter-qPCR was applied to *Borrelia*-spiked blood samples. Consistent copy numbers from technical repeats were recovered from samples with ≥ 1 spike-in *Borrelia* cell (**Figure 4A**). This indicates that the Ter-qPCR can potentially detect as low as one *Borrelia* cell from a blood sample. In contrast, the blood sample with 0.1 of a *Borrelia* cell (mimicking the scenario of an extremely low level of *Borrelia* presence in the blood) displayed one copy number out of six repeats (**Figure 4A**). It is already established that the number of *Borrelia* cells circulating in the blood is extremely low and is often at the lower end of the detection limit of qPCR (Brettschneider et al., 1998). Therefore, it is common to get one PCR amplification out of technical repeats due to stochastic effect when in low concentration (Primus et al., 2018). To reflect the low and random distribution nature of *Borrelia* cells in blood, we adopted the following rule for recording copy numbers: the replicate that did not generate a copy number (displayed as 'failed qPCR') was scored 'zero' (Primus et al., 2018). The 'zero' *Borrelia* presence in blood was manifested in our later study analysing LD patient samples.

To better understand the reliability of the Ter-qPCR, simple linear regression analysis was performed. As seen in **Figure 4B**, a linear association ($R^2 = 0.9891$) was observed between the amount of spiked *Borrelia* cells and the resulting Cq values, which demonstrates that the signal intensity of Ter-qPCR correlates with the '*Borrelia* load.' In other words, it appears that the Ter-qPCR can detect as low as one *Borrelia* per 300 μ l blood, which is equivalent to 3.3 *Borrelia* cells per ml of blood. This is really promising, bearing in mind that evidence from published studies indicates that *Borrelia* presence in LD patients can range from 1-100 cells/ml (Liveris et al., 2012). Therefore this single cell sensitivity allows the Ter-qPCR test to change the way *Borrelia* infection is detected (Buchanan et al., 2017). To put this in context, the current practice to circumvent the bottleneck of low numbers of *Borrelia* circulating in blood is either to culture prior to qPCR or to sample large volumes of blood to artificially increase the amount of PCR templates. Both methods have obvious drawbacks (Brettschneider et al., 1998). Intuitively, by targeting endogenous multi-copy genes, the Ter-qPCR assay offers a much more elegant and reliable way of increasing the amount of PCR template.

We initially chose the phenol method to extract DNA from blood as it is the method of choice when it comes to extracting phage DNA (Pickard, 2009). Although the phenol extraction method is in many ways a gold standard, it is cumbersome. To improve the scaling of the assay, we tested commercial DNA extraction kits, such as the DNeasy Blood and Tissue Kit (a column filtration system) and Maxwell RSC Viral Total Nucleic Acid Purification Kit (a magnetic beads-based system) to see whether they could replace the solvent-based method.

Despite a significant effort, including comparisons with bacterial chromosome-targeting 16S qPCR, the phenol extraction




method outperformed the other two commercial methods. Thus, the phenol method was used throughout this study. As shown in **Figure 5**, regardless of qPCR methods, the phenol approach generated a consistently higher copy number compared to the other two DNA extraction methods. The Ter-qPCR coupled with the phenol method produced significantly higher copy numbers than their counterparts of the 16S qPCR from all spiked samples. Additionally, the Ter-qPCR generated robust copy numbers (three positives out of three replicates) from blood spiked with one *Borrelia* cell (**Figure 5**), but the 16S qPCR only displayed amplification once from the triplicate repeats of the same sample. The outstanding sensitivity of Ter-qPCR can also be seen from the markedly lower Cq values (therefore high amounts of PCR target) of the Ter-qPCR than that of the 16S qPCR

when both qPCRs were targeting the same *B31* genomic DNA (**Figure 6B**). The competitive advantage of targeting multicopy genes can also be seen in that the copy numbers determined by the Ter-qPCR were consistently higher than the number of spiked *Borrelia*, while the copy numbers established via the 16S qPCR were numerically about the same as the input *Borrelia* number (**Figure 5**).

Spontaneous Prophage Induction Provides Unique Discriminatory Power


It is logical that multicopy PCR targets will lead to higher sensitivity when compared to a single-copy PCR target (Luo et al., 2010). We determined whether the prophage encoded



genes would provide additional sensitivity to detect infections. Since some prophages can escape from their bacterial hosts either by chemical induction or spontaneous prophage induction (SPI), it is entirely possible that multiple *Borrelia* prophages could be released into the blood where they magnify the diagnostic signals and thus can be detected. In the case of *Borrelia*, *terL*-carrying cp32 prophages have been demonstrated to be susceptible to 1-methyl-3-nitroso-nitroguanidine (MNNG) induction during *in vitro* culturing (Eggers and Samuels, 1999). We hypothesize that *Borrelia* prophages are also capable of SPI which increases the chances of *Borrelia* prophages being induced in the human body.

To test this SPI hypothesis, we conducted morphological and molecular studies to detect phage presence in cell-free filtrates of *Borrelia* cultures prior and post 36 h incubation. As shown in **Figure 6A**, transmission electron microscope (TEM) analysis revealed particles morphologically resembling podoviruses (icosahedral heads and very short tails) (Ackermann, 2003) in the polyethylene glycol (PEG)-purified phage fraction derived from *Borrelia* cultures post 36 h incubation. The PEG product was positive to the Ter-qPCR but negative to the *Borrelia* 16S qPCR (**Figure 6B**). The Ter-qPCR positive result therefore indicates the presence of cp32 DNA (prophage) in the PEG product. Meanwhile, the PEG product derived from *Borrelia* culture prior incubation showed no phage-like particles and was negative to both the Ter-qPCR and the *Borrelia* 16S qPCR.

Our spontaneous induction data led us to predict that the prophage-based Ter-qPCR would generate a much stronger *Borrelia* signal than bacteria-based qPCR, because LD *Borrelia* species are tissue bound and thus can only circulate in blood transiently and in very low numbers (Liang et al., 2020). In contrast, under the scenario of induction, prophages are released into bloodstream, and thus can be a ‘marker’ indicating the presence of *Borrelia*, even though *Borrelia* cells can be hiding and not circulating in the blood. This situation of detecting free phage DNA from human blood bears some resemblance to identifying cell-free circulating DNA (cfDNA) as with cancer diagnosis (Phallen et al., 2017). Interestingly, the same challenge also stands in terms of the method of choice for isolating cfDNA (Hufnagl et al., 2013). Phenol chloroform was also highly efficient in recovering cfDNA from clinical samples (Hufnagl et al., 2013). Free phages have been discovered from a range of clinical samples, including blood (Brown-Jaque et al., 2016). Their biological significance remains to be understood. Considering the fact that metabolic active bacteria can better support phage reproduction (Burns et al., 2015), a high level of certain phages in the blood would indicate active infections of their respective bacteria, i.e., a strong *terL* signal would implicate active *Borrelia* infection. Given the fact that most pathogenic bacteria carry many inducible (including SPI) prophages, the




rational of diagnosing bacteria by detecting their 'breakaway' prophages could change the current bacteria-focused paradigm of detecting bacterial infections.

Performance of the Ter-qPCR Against Clinical Samples

As a final important evaluation step of this work, the Ter-qPCR was applied to 78 individuals belonging to three categories (early LD, late LD patients and healthy volunteers) who were diagnosed by Dr. LT (Cameron et al., 2014). We intended to establish the feasibility of the Ter-qPCR to detect LD. Copy numbers were determined from both blood and serum samples with three technical repeats for each sample type. The technical repeats that did not show detectable copy numbers were scored 'zero'. The raw data was presented in the **Supplementary Table**. Visually, there are many more 'zero' scores from serum than blood samples, and the mean and median values obtained from blood samples in each category are much higher than those from sera (**Supplementary Table**). The higher copy numbers determined from the whole blood as compared to the serum samples reflects *Borrelia's* intracellular life cycle and the fact that Ter-qPCR can detect both prophages that are inside or outside of the *Borrelia* cells (Klose et al., 2021). Therefore, whole blood is a more robust sample source from which to diagnose LD using qPCR assay.

Overall, most of samples showed a low *terL* copy number (<10), which is consistent with the current estimation of a low concentration of *Borrelia* circulating in the blood (**Supplementary Table**). It is also common to have variation among technical repeats, for example, three technical repeats of the patient No. 25 showed copy numbers of 10, 2.8, and 0, respectively (**Supplementary Table**). This qPCR variability is due to the stochastic effect of having a low number of PCR templates, and has been observed in PCR detection of low level bacteria in blood before (Wei et al., 2016). Markedly differences were observed in the mean copy number of early LD (2.4), and late LD (6.9), as well as healthy volunteers (0.8), which suggests a potential positive correlation between the severity of LD and the copy numbers, i.e., higher copy numbers in late LD patients, in contrast to lower copy numbers in early LD patients and healthy volunteers. Also, very encouragingly, the median values from the early (2.0) and late (1.8) LD patients are numerically higher than those of the healthy volunteers (0.7) (**Supplementary Table**). The fact that some healthy volunteers showed positive with copy numbers, indicates possible asymptomatic *Borrelia* carriage (Primus et al., 2018). Most importantly, the apparent marked difference in copy numbers from the three categories is supported by statistical analysis. As shown in **Figure 7**, Mann-Whitney *U* test revealed significant differences between early LD, late LD patients and healthy volunteers in terms of *terL* levels determined from whole blood, which offers objective evidence to prove that LD is a fact, and that the early and late LD stages do exist. This statistics-backed difference also suggests the potential application of the Ter-qPCR to distinguish early LD from healthy asymptomatic *Borrelia* carrier.



We conclude that our prophage marker has the ability to differentiate between early and late LD patients. For example, the Ter-qPCR could be used to monitor LD treatment outcomes, to indicate which treatment option may work best, and to help clinicians measure recovery. We are currently validating a *terL*-based assay targeting RF and *B. miyamotoi*, respectively, working toward a 'multiplex' PCR aiming to detect and differentiate LD *Borrelia* spp., RF *Borrelia* spp., and *B. miyamotoi* from a single test.

Rapid and accurate detection of microbial pathogens in blood using qPCR methods is promising, but hampered by the low-level presence of bacteria in circulating blood, false signals and reduced sensitivity due to unspecific amplification of human DNA. The data presented in this study demonstrates for the first time that targeting phage DNA in blood could offer a rapid diagnosis of bacterial infections and could change the paradigm in the field of PCR detection of bacteria in general.

MATERIALS AND METHODS

Phylogenetic Analysis

Phylogenetic analysis was constructed using the program Molecular Evolutionary Genetics Analysis (MEGA) 7 according to the previous established method (Shan et al., 2012, 2014). Neighbor-Joining (NJ) with a maximum composite likelihood

model and Maximum Likelihood (ML) based on the Tamura-Nei model analyses were conducted on a nucleotide data set of *terL* genes. Support for clades were estimated using a bootstrap analysis implemented in MEGA using 3,000 replicates. The trees were rooted with phage Lambda (NC_001416) as an outgroup.

Borrelia Strains and Cultures

The *Borrelia* strains used in this study are listed in Table 1. Ten strains were provided by Professor Sven Bergström, Department of Molecular Biology, Umea University, Sweden. Seven strains were purchased from the Pasteur Institute and DSMZ (German Collection of Microorganisms and Cell Cultures GmbH). Two strains were provided by the Center for Disease Control and Prevention (CDC), United States, and two by Cecilia Hizo-Teufel from the German National Reference Centre for *Borrelia*. *Borrelia* cells were grown in 15 ml Falcon™ conical tubes with a culture volume of 14 ml of Barbour-Stoenner-Kelly (BSK) II medium with 7% rabbit serum (referred to as complete BSKII or c-BSKII) at 35°C without agitation as previously reported (Zuckert, 2007). All culture media was filter sterilized via 0.22 µm pore size filters. Visualization and counting of *Borrelia* was performed using phase contrast microscopy (Ceti Magnum Trinocular) and a Fuchs Rosenthal Disposable Counting Chamber (C-Chip, NanoEnTek).

DNA Extraction Methods

A modified phenol-chloroform method was used to extract DNA from blood and serum samples. In brief, samples were treated with ammonium hydroxide (Santino et al., 2008) followed by the classic phenol chloroform DNA extraction method (Sambrook and Russell, 2006). The resulting DNA pellet was air dried for 5 min, dissolved in 40 µl Tris-Cl (10 mM, pH 8.5), and kept at -20°C. DNeasy Blood and Tissue Kit and Maxwell RSC Viral Total Nucleic Acid Purification Kit were used according to the respective manufacturer instructions. The Thermo Scientific™ NanoDrop™ One Spectrophotometer was used to measure the quantity and quality of DNA samples.

The Ter-qPCR

Primers and probe were designed using the PrimerQuest® Tool based on an alignment of phage *terL* genes from 13 cp32 plasmids (cp32-1 to cp32-13) carried by *B. burgdorferi* s.l strains. The resulting Ter-qPCR amplified a 147 bp target region (Shan et al., 2018). The fluorogenic probe was labeled with 6-carboxyfluorescein (FAM) fluorescent reporter dye at the 5'-end, an internal ZEN™ Quencher and an Iowa Black Fluorescent Quencher (IBFQ) to the 3' (5'FAM/ZEN/3'IBFQ). To rule out PCR inhibition and avoid false negatives, the Ter-qPCR was duplexed with an internal amplification control (IAC) qPCR that generated a 145 bp PCR product (Deer et al., 2010). The IAC DNA (accession number FJ357008.1) was synthesized by IDT and added to each Ter-qPCR template. The IAC probe was fluorescently labeled with the fluorescent dye of JOE at the 5'-end. The primers and probe targeting the *Borrelia* 16S rRNA gene were adopted from

a published paper (O'Rourke et al., 2013). All the primers, probes and PrimeTime Gene Expression Master Mix were supplied by IDT.

Construction of the Standard DNA

For absolute quantification, a plasmid carrying the phage *terL* gene fragment (named as Ter-plasmid) was constructed and used as the standard curve. Specifically, a pair of PCR primers was designed using Primer Blast to amplify a 721 bp region of the phage *terL* gene (GenBank accession NC_000948), embracing the 147-bp Ter-qPCR product region. The primers were FTer721:AGACTAAGATGCGGGCAAGA and RTer721:TTGCATCAAGAGCGTCATCA. PCRs were carried out in a LabCycler (SensoQuest GmbH) in a total volume of 50 µl, containing 0.25 mM dNTPs, 3 mM MgCl₂, 3 µM primers, 50 ng template DNA, 0.5 unit of Taq polymerase (Bioline), and 5 µl 10 × Taq buffer (Bioline). Amplification conditions were: 94°C for 2 min, 30 cycles of 94°C for 30 s, 50°C for 30 s, 72°C for 1 min, with a final extension of 10 min at 72°C. PCR products were gel-purified using a Qiagen gel extraction kit, and subjected to cloning using the NEB® PCR Cloning Kit according to the manufacturer's instructions. The recombinant Ter-plasmid DNA carrying the 721-bp *terL* gene was purified using the Qiagen Plasmid Kit from positive clones. The concentration of the Ter-plasmid was converted into DNA copy number on 20 January 2018 (Staroscik, 2004).

PCR Setup

The Ter-qPCR duplexed with the IAC assay was conducted in a 20 µl final reaction volume containing 10 µl 2X PrimeTime Master Mix, with each primer and each probe at a final concentration of 0.5 and 0.25 µM, respectively, 4 µl template DNA, 2 µl IAC (200 genome copies) and nuclease-free water. Standard thermal cycling conditions (Applied Biosystems™ 7500 Fast Real-Time PCR System) were followed with an initial step of 3 min at 95°C (polymerase activation), 45 cycles of 15 s at 95°C (denaturation) and 1 min at 60°C (annealing/extension). The *Borrelia* 16S qPCR setup was carried out according to the previous report (O'Rourke et al., 2013).

A non-template control (NTC), a positive control of 10 ng *B. burgdorferi* B31 (labeled as B31) DNA and a standard curve made of a series of five tenfold dilutions of the Ter-plasmid DNA (10⁶–10²) were included in each run. The qPCR result was analyzed and quantified according to the standard curve using FAST7500 software v2.3. For the Ter-qPCR to be valid, the IAC signal should always be produced regardless of the presence or absence of template DNA. All samples were tested in triplicate.

Analytical Specificity and Sensitivity

The analytical specificity of the Ter-qPCR assay was determined using both *in silico* and *in vitro* analyses. *In silico* analysis of the primer and probe set was carried out using BLAST and

Primer-BLAST (Ye et al., 2012), and UCSC *in silico* PCR². For *in vitro* analysis, the Ter-qPCR was applied to DNA extracted from a panel of *Borrelia* strains that cause LD and RF (Table 1), and microbial species that have been used in the lab, including *Clostridium difficile*, *Clostridium perfringens*, *Escherichia coli*, *Pseudomonas aeruginosa*, *Streptococcus pneumoniae*, *Staphylococcus aureus*, *Burkholderia thailandensis*, *Burkholderia pseudomallei*, *Haemophilus influenzae* and *Salmonella enterica*. Additionally, human female and male DNA (Promega, G1521 and G1471), and DNA extracted using the phenol method from human whole blood (Cat#: SER-WB10ML from Cambridge Biosciences) were also tested using the Ter-qPCR.

The analytical sensitivity of the Ter-qPCR was firstly evaluated with five tenfold dilutions of the Ter-plasmid (10^6 to 10^2) and B31 DNA (40 ng to 4 pg), respectively. Each dilution was tested with three replicates to determine the PCR linearity and amplification efficiency. The LoD was then estimated by testing Ter-plasmid dilutions from 1000 to 100, 80, 60, 40, 20, 10, 5, and 1 copies/PCR. Ten replicates were used for each dilution. To mimic the real situation of analyzing DNA extracted from human samples, all Ter-plasmid serial dilution experiments were conducted with the presence of background human DNA 125 ng per PCR. Probit analysis via the SPSS software was performed to calculate the LoD with 95% probability (Forootan et al., 2017).

Spiked Blood Samples

Actively growing B31 cultures in the early exponential phase (around 10^6 spirochaetes/ml) was used to spike human whole blood (in duplicate) to generate a final amount of 10^5 , 10^4 , 10^3 , 10^2 , 10, 1, and 0.1 spike-in B31 cells in 300 μ l of blood. DNA extraction was carried out using the modified phenol-chloroform method. To compare the different DNA extraction methods, a subset of the B31-spiked blood samples (corresponding to 10^3 , 10^2 , 10, and 1 B31 cells per 300 μ l of blood) were also used for DNeasy and Maxwell DNA extractions, respectively. All the resulting DNAs were analyzed by both the Ter-qPCR and the *Borrelia* 16S qPCR.

Spontaneous Phage Induction and TEM

14 ml of early exponential phase, actively growing B31 cultures (7×10^5 - 10^6 cells/ml, dominated by free spirochaetal forms) were spun down (6 000 g for 20 min) and washed twice with sterile PBS. The resulting pellets were resuspended in 14 ml c-BSKII and incubated for 36 h at 35°C. Portions of the B31 suspension prior and post 36 h incubation were centrifuged down, the resulting supernatants were filtered through 0.1 μ m pore filters. Extraction of phages from the filtrates were carried out using PEG precipitation (Sambrook and Russell, 2001). The PEG-purified phage product was used for DNA extraction (Sambrook and Russell, 2006) and TEM at the Core Biotechnology Services at the University of Leicester (Shan et al., 2012). The resulting DNA was examined by the Ter-qPCR and the *Borrelia* 16S qPCR assays.

²<https://genome.ucsc.edu/cgi-bin/hgPcr>

Ethics Statement and Clinical Samples

This study was carried out in accordance with protocols reviewed and approved by the Ethics Committee, Comités de protection des personnes (CPP) with investigator reference of Etude Phelix 01617 V1 and CPP reference of 17031. All participants were diagnosed by Dr. LT according to the ILADS (International Lyme and Associated Diseases Society) guidelines (Cameron et al., 2014). Some of individuals who did not recall a tick bite and had no LD-like symptoms (ILADS guidelines) served as healthy volunteers. All healthy volunteers were also negative to Lyme C6 ELISA that was performed according to manufacturer's instructions (Immunitics: *B. burgdorferi* (Lyme) ELISA kit: DK-E352-096). A total of 312 samples (156 whole blood and 156 serum samples) were collected from 78 individuals between April-June 2017 (23 healthy volunteers with no 'identifiable' LD symptoms, 13 early stage and 42 late stage LD patients). For everyone involved, two tubes of serum and two tubes of Ethylenediaminetetraacetic acid (EDTA)-treated whole blood (approximately one ml in each tube) were provided. Samples were provided in a coded, de-identified manner to preserve patient anonymity. Informed consent was obtained from all participants. The modified phenol chloroform DNA extraction method was applied to all the samples in a duplicate manner. Therefore, there were four DNA samples generated from one individual, two from the whole blood and two from the serum. Triplicate qPCR was applied to each DNA sample, which led to 12 Ter-qPCR data (six from whole blood, six from serum) expressed in copy numbers according to the standard curve for any one individual.

Statistical Analysis

Graphpad Prism 8.4.3. was used for statistical analysis. Descriptive statistics and the D'Agostino-Pearson normality test were used to assess the data distribution. Mann-Whitney U tests were used to determine the significance of the difference between early, late LD patients and healthy volunteers. Furthermore, Probit analysis was carried out via the SPSS software suite (IBM SPSS Statistics 25) to estimate the LoD. The differences were not considered to be significant when the p-values were greater than 0.05. Linear regressions were used to establish correlations between the serial dilution of Ter-plasmids/B31 DNAs and Cq values.

DATA AVAILABILITY STATEMENT

The Ter-qPCR assay includes a set of oligonucleotide primers and Taqman[®] probes and plasmid DNA as the standard for *in vitro* quantitative detection of *Borrelia* species causing LD. All primers and probes are described in the patent application Ref. P184103.EP.01/T. Other relevant data supporting the findings of the study are available in this article and its **Supplementary Information 1–5** and **Supplementary Table**, or from the corresponding author upon request.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Comités de protection des personnes (CPP). The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

JS and MC co-conceived the initial idea. JS expanded the initial idea into a coherent scientific project, designed primers and probes and performed in-depth data analysis. YJ was responsible for experimentation and optimization, data collecting and initial data interpretation. JS and YJ co-wrote the manuscript. MC proofread the manuscript and provided valuable comments and suggestions. FP helped with bioinformatic and phylogenetic analyses. LT carried out the ethical application, clinical samples selection and some data analysis. All authors contributed to the article and approved the submitted version.

REFERENCES

- Ackermann, H. W. (2003). Bacteriophage observations and evolution. *Res. Microbiol.* 154, 245–251. doi: 10.1016/s0923-2508(03)00067-6
- Anderson, B. E., and Neuman, M. A. (1997). *Bartonella* spp. as emerging human pathogens. *Clin. Microbiol. Rev.* 10, 203–219. doi: 10.1128/cmr.10.2.203-219.1997
- Argov, T., Sapir, S. R., Pasechnek, A., Azulay, G., Stadnyuk, O., Rabinovich, L., et al. (2019). Coordination of cohabiting phage elements supports bacteria–phage cooperation. *Nat. Commun.* 10:5288. doi: 10.1038/s41467-019-13296-x
- Bergström, S., and Normark, J. (2018). Microbiological features distinguishing Lyme disease and relapsing fever spirochetes. *Wien. Klin. Wochenschr.* 130, 484–490. doi: 10.1007/s00508-018-1368-2
- Brettschneider, S., Bruckbauer, H., Klugbauer, N., and Hofmann, H. (1998). Diagnostic value of PCR for detection of *Borrelia burgdorferi* in skin biopsy and urine samples from patients with skin borreliosis. *J. Clin. Microbiol.* 36, 2658–2665. doi: 10.1128/jcm.36.9.2658-2665.1998
- Brisson, D., Zhou, W., Jutras, B. L., Casjens, S., and Stevenson, B. (2013). Distribution of cp32 prophages among Lyme disease-causing spirochetes and natural diversity of their lipoprotein-encoding erp loci. *Appl. Environ. Microbiol.* 79, 4115–4128. doi: 10.1128/aem.00817-13
- Brown-Jaque, M., Muniesa, M., and Navarro, F. (2016). Bacteriophages in clinical samples can interfere with microbiological diagnostic tools. *Sci. Rep.* 6:33000. doi: 10.1038/srep33000
- Buchanan, C. M., Wood, R. L., Hoj, T. R., Alizadeh, M., Bledsoe, C. G., Wood, M. E., et al. (2017). Rapid separation of very low concentrations of bacteria from blood. *J. Microbiol. Methods* 139, 48–53. doi: 10.1016/j.mimet.2017.05.004
- Burns, N., James, C. E., and Harrison, E. (2015). Polylysogeny magnifies competitiveness of a bacterial pathogen *in vivo*. *Evol. Appl.* 8, 346–351. doi: 10.1111/eva.12243
- Bustin, S. A., Benes, V., Garson, J. A., Hellems, J., Huggett, J., Kubista, M., et al. (2009). The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. *Clin. Chem.* 55, 611–622. doi: 10.1373/clinchem.2008.112797
- Cameron, D. J., Johnson, L. B., and Maloney, E. L. (2014). Evidence assessments and guideline recommendations in Lyme disease: the clinical management of known tick bites, erythema migrans rashes and persistent disease. *Expert Rev. Anti Infect. Ther.* 12, 1103–1135. doi: 10.1586/14787210.2014.940900
- Carrias, A., Welch, T. J., Waldbieser, G. C., Mead, D. A., Terhune, J. S., and Liles, M. R. (2011). Comparative genomic analysis of bacteriophages specific to the

ACKNOWLEDGMENTS

We would like to thank Dr. Andrew Millard and Stacy Guiock for their help in proofreading the manuscript. We gratefully acknowledge the main funding received toward the study from the Phelix Research and Development (Phelix R&D, 37 Langton Street, SW10 0JL London, United Kingdom, the Charity Number 1156666), the ‘Giff’ funding from Lymefonds, Netherlands (ANBI-number: 858578438), and the University of Leicester Drug Discovery and Diagnostics (LD3) spring fund 2018.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fmicb.2021.651217/full#supplementary-material>

- channel catfish pathogen *Edwardsiella ictaluri*. *Virology* 8:6. doi: 10.1186/1743-422x-8-6
- Casjens, S. R., Gilcrease, E. B., Vujadinovic, M., Mongodin, E. F., Luft, B. J., Schutzer, S. E., et al. (2017). Plasmid diversity and phylogenetic consistency in the Lyme disease agent *Borrelia burgdorferi*. *BMC Genomics* 18:165. doi: 10.1186/s12864-017-3553-5
- Casjens, S. R., Mongodin, E. F., Qiu, W. G., Luft, B. J., Schutzer, S. E., Gilcrease, E. B., et al. (2012). Genome stability of Lyme disease spirochetes: comparative genomics of *Borrelia burgdorferi* plasmids. *PLoS One* 7:14. doi: 10.1371/journal.pone.0033280
- Chaaya, G., Jaller-Char, J. J., and Ali, S. K. (2016). Beyond the bull's eye: recognizing Lyme disease. *J. Fam. Pract.* 65, 373–379.
- Deer, D. M., Lampel, K. A., and Gonzalez-Escalona, N. (2010). A versatile internal control for use as DNA in real-time PCR and as RNA in real-time reverse transcription PCR assays. *Letts. Appl. Microbiol.* 50, 366–372. doi: 10.1111/j.1472-765x.2010.02804.x
- Eggers, C., and Samuels, D. S. (2000). Molecular evidence for a new bacteriophage of *Borrelia burgdorferi*. *J. Bacteriol.* 181, 7308–7313. doi: 10.1128/JB.181.23.7308-7313.1999
- Eggers, C. H., and Samuels, D. S. (1999). Molecular evidence for a new bacteriophage of *Borrelia burgdorferi*. *J. Bacteriol.* 181, 7308–7313. doi: 10.1128/JB.181.23.7308-7313.1999
- Forootan, A., Sjöback, R., Björkman, J., Sjögreen, B., Linz, L., and Kubista, M. (2017). Methods to determine limit of detection and limit of quantification in quantitative real-time PCR (qPCR). *Biomol. Detect. Quantif.* 12, 1–6. doi: 10.1016/j.bdq.2017.04.001
- Gosiewski, T., Szała, L., Pietrzyk, A., Brzychczy-Włoch, M., Heczko, P. B., and Bulanda, M. (2014). Comparison of methods for isolation of bacterial and fungal DNA from human blood. *Curr. Microbiol.* 68, 149–155. doi: 10.1007/s00284-013-0451-1
- Hufnagl, C., Stöcher, M., Moik, M., Geisberger, R., and Greil, R. (2013). A modified phenol-chloroform extraction method for isolating circulating cell free DNA of tumor patients. *J. Nucleic Acids Invest.* 4:e1. doi: 10.4081/jnai.2013.4282
- Klose, M., Scheungrab, M., Luckner, M., Wanner, G., and Linder, S. (2021). FIB-SEM-based analysis of *Borrelia* intracellular processing by human macrophages. *J. Cell Sci.* 134:jcs252320. doi: 10.1242/jcs.252320
- Koetsveld, J., Draga, R. O. P., Wagemakers, A., Manger, A., Oei, A., Visser, C. E., et al. (2017). *In vitro* susceptibility of the relapsing-fever spirochete *Borrelia miyamotoi* to antimicrobial agents. *Antimicrob. Agents Chemother.* 61, e535–e517. doi: 10.1128/AAC.00535-17

- Kralik, P., and Ricchi, M. (2017). A basic guide to real time PCR in microbial diagnostics: definitions, parameters, and everything. *Front. Microbiol.* 8:108. doi: 10.3389/fmicb.2017.00108
- Kugeler, K., Schwartz, A., Delorey, M., Mead, P., and Hinckley, A. (2021). Estimating the frequency of Lyme disease diagnoses, United States, 2010–2018. *Emerg. Infect. Dis. J.* 27, 616–619. doi: 10.3201/eid2702.202731
- Liang, L., Wang, J., Schorter, L., Nguyen Trong, T. P., Fell, S., Ulrich, S., et al. (2020). Rapid clearance of *Borrelia burgdorferi* from the blood circulation. *Parasit. Vectors* 13:191. doi: 10.1186/s13071-020-04060-y
- Liveris, D., Schwartz, I., McKenna, D., Nowakowski, J., Nadelman, R., Demarco, J., et al. (2012). Comparison of five diagnostic modalities for direct detection of *Borrelia burgdorferi* in patients with early Lyme disease. *Diagn. Microbiol. Infect. Dis.* 73, 243–245. doi: 10.1016/j.diagmicrobio.2012.03.026
- Lohr, B., Fingerle, V., Norris, D. E., and Hunfeld, K.-P. (2018). Laboratory diagnosis of Lyme borreliosis: current state of the art and future perspectives. *Crit. Rev. Clin. Lab. Sci.* 55, 219–245. doi: 10.1080/10408363.2018.1450353
- Luo, R. F., Scahill, M. D., and Banaei, N. (2010). Comparison of single-copy and multicopy real-time PCR targets for detection of *Mycobacterium tuberculosis* in paraffin-embedded tissue. *J. Clin. Microbiol.* 48, 2569–2570. doi: 10.1128/jcm.02449-09
- Minasyan, H. (2019). Sepsis: mechanisms of bacterial injury to the patient. *Scand. J. Trauma Resusc. Emerg. Med.* 27:19. doi: 10.1186/s13049-019-0596-4
- Moore, A., Nelson, C., Molins, C., Mead, P., and Schriefer, M. (2016). Current guidelines, common clinical pitfalls, and future directions for laboratory diagnosis of Lyme disease, United States. *Emerg. Infect. Dis.* 22, 1169–1177. doi: 10.3201/eid2207.151694
- Opota, O., Jatou, K., and Greub, G. (2015). Microbial diagnosis of bloodstream infection: towards molecular diagnosis directly from blood. *Clin. Microbiol. Infect.* 21, 323–331. doi: 10.1016/j.cmi.2015.02.005
- O'Rourke, M., Traweger, A., Lusa, L., Stupica, D., Maraspin, V., Barrett, P. N., et al. (2013). Quantitative detection of *Borrelia burgdorferi* sensu lato in erythema migrans skin lesions using internally controlled duplex real time PCR. *PLoS One* 8:e63968. doi: 10.1371/journal.pone.0063968
- Pavia, C. S., and Plummer, M. M. (2018). Transfusion-associated Lyme disease – although unlikely, it is still a concern worth considering. *Front. Microbiol.* 9:2070. doi: 10.3389/fmicb.2018.02070
- Pavšič, J., Žel, J., and Milavec, M. (2016). Assessment of the real-time PCR and different digital PCR platforms for DNA quantification. *Anal. Bioanal. Chem.* 408, 107–121. doi: 10.1007/s00216-015-9107-2
- Phallen, J., Sausen, M., Adelff, V., Leal, A., Hruban, C., White, J., et al. (2017). Direct detection of early-stage cancers using circulating tumor DNA. *Sci. Transl. Med.* 9:eaan2415. doi: 10.1126/scitranslmed.aan2415
- Pickard, D. J. (2009). Preparation of bacteriophage lysates and pure DNA. *Methods Mol. Biol.* 502, 3–9. doi: 10.1007/978-1-60327-565-1_1
- Pratama, A. A., Chaib De Mares, M., and Van Elsas, J. D. (2018). Evolutionary history of bacteriophages in the genus *Paraburkholderia*. *Front. Microbiol.* 9:835. doi: 10.3389/fmicb.2018.00835
- Primus, S., Akoolo, L., Schlachter, S., Gedroic, K., Rojzman, A. D., and Parveen, N. (2018). Efficient detection of symptomatic and asymptomatic patient samples for *Babesia microti* and *Borrelia burgdorferi* infection by multiplex qPCR. *PLoS One* 13:e0196748. doi: 10.1371/journal.pone.0196748
- Ravagnan, S., Tomassone, L., Montarsi, F., Krawczyk, A. I., Mastrolilli, E., Sprong, H., et al. (2018). First detection of *Borrelia miyamotoi* in *Ixodes ricinus* ticks from northern Italy. *Parasit. Vectors* 11:130. doi: 10.1186/s13071-018-2713-z
- Sambrook, J., and Russell, D. W. (2001). *Molecular Cloning: A Laboratory Manual*. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory.
- Sambrook, J., and Russell, D. W. (2006). Purification of nucleic acids by extraction with phenol:chloroform. *Cold Spring Harb. Protoc.* 2006:db.rot4455. doi: 10.1101/pdb.prot4455
- Santino, I., Berlutti, F., Pantanella, F., Sessa, R., and Del Piano, M. (2008). Detection of *Borrelia burgdorferi* sensu lato DNA by PCR in serum of patients with clinical symptoms of Lyme borreliosis. *FEMS Microbiol. Lett.* 283, 30–35. doi: 10.1111/j.1574-6968.2008.01134.x
- Schutzer, S. E., Body, B. A., Boyle, J., Branson, B. M., Dattwyler, R. J., Fikrig, E., et al. (2019). Direct diagnostic tests for Lyme disease. *Clin. Infect. Dis.* 68, 1052–1057. doi: 10.1093/cid/ciy614
- Schutzer, S. E., Fraser-Liggett, C. M., Casjens, S. R., Qiu, W.-G., Dunn, J. J., Mongodin, E. F., et al. (2011). Whole-genome sequences of thirteen isolates of *Borrelia burgdorferi*. *J. Bacteriol.* 193:1018. doi: 10.1128/jb.01158-10
- Shan, J., Clokie, M. R., and Teulières, L. (2018). *Phage-Based Detection of Borreliosis and Means Therefor*. Google Patent No. PCT/GB2017/053323.
- Shan, J., Korbsrisate, S., Withatanung, P., Adler, N. L., Clokie, M. R. J., and Galyov, E. E. (2014). Temperature dependent bacteriophages of a tropical bacterial pathogen. *Front. Microbiol.* 5:599. doi: 10.3389/fmicb.2014.00599
- Shan, J., Patel, K. V., Hickenbotham, P. T., Nale, J. Y., Hargreaves, K. R., and Clokie, M. R. (2012). Prophage carriage and diversity within clinically relevant strains of *Clostridium difficile*. *Appl. Environ. Microbiol.* 78, 6027–6034. doi: 10.1128/aem.01311-12
- Starosik, A. (2004). *Calculator for Determining the Number of Copies of a Template*. Available online at: <http://cels.uri.edu/gsc/cndna.html> (accessed January 20, 2018).
- Sun, S., Gao, S., Kondabagil, K., Xiang, Y., Rossmann, M. G., and Rao, V. B. (2012). Structure and function of the small terminase component of the DNA packaging machine in T4-like bacteriophages. *Proc. Natl. Acad. Sci. U.S.A.* 109, 817–822. doi: 10.1073/pnas.1110224109
- Takano, A., Goka, K., Une, Y., Shimada, Y., Fujita, H., Shiino, T., et al. (2010). Isolation and characterization of a novel *Borrelia* group of tick-borne borreliae from imported reptiles and their associated ticks. *Environ. Microbiol.* 12, 134–146. doi: 10.1111/j.1462-2920.2009.02054.x
- Telford, S. R. III, Goethert, H. K., Molloy, P. J., Berardi, V. P., Chowdri, H. R., Gugliotta, J. L., et al. (2015). *Borrelia miyamotoi* disease: neither Lyme disease nor relapsing fever. *Clin. Lab. Med.* 35, 867–882. doi: 10.1016/j.cll.2015.08.002
- Theel, E. S., Aguero-Rosenfeld, M. E., Pritt, B., Adem, P. V., and Wormser, G. P. (2019). Limitations and confusing aspects of diagnostic testing for neurologic Lyme disease in the United States. *J. Clin. Microbiol.* 57, 01406–01418. doi: 10.1128/JCM.01406-18
- Waddell, L. A., Greig, J., Mascarenhas, M., Harding, S., Lindsay, R., and Ogden, N. (2016). The accuracy of diagnostic tests for Lyme disease in humans, a systematic review and meta-analysis of north American research. *PLoS One* 11:e0168613. doi: 10.1371/journal.pone.0168613
- Wei, B., Chen, L., Kibukawa, M., Kang, J., Waskin, H., and Marton, M. (2016). Development of a PCR Assay to detect low level *Trypanosoma cruzi* in blood specimens collected with PAXgene blood DNA tubes for clinical trials treating chagas disease. *PLoS Negl. Trop. Dis.* 10:e0005146. doi: 10.1371/journal.pntd.0005146
- Wormser, G. P., Shapiro, E. D., and Fish, D. (2019). *Borrelia miyamotoi*: an emerging tick-borne pathogen. *Am. J. Med.* 132, 136–137. doi: 10.1016/j.amjmed.2018.08.012
- Ye, J., Coulouris, G., Zaretskaya, I., Cutcutache, I., Rozen, S., and Madden, T. L. (2012). Primer-BLAST: a tool to design target-specific primers for polymerase chain reaction. *BMC Bioinformatics* 13:134. doi: 10.1186/1471-2105-13-134
- Zuckert, W. R. (2007). Laboratory maintenance of *Borrelia burgdorferi*. *Curr. Protoc. Microbiol.* 4, 12C.1.1–12C.1.10. doi: 10.1002/9780471729259.mc12c01s4

Conflict of Interest: JS, LT, and MC are listed as inventors in the patent application No. PCT/GB2017/053323.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Shan, Jia, Teulières, Patel and Clokie. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.